Age at cancer diagnosis, non-O blood group and asparaginase therapy are independently associated with deep venous thrombosis in pediatric oncology patients: A risk model

Impact of baseline clinical and laboratory features on the risk of thrombosis in children with acute lymphoblastic leukemia: A prospective evaluation

“…Most importantly, we confirmed that ABO blood group is an independent risk factor of sTE in children with ALL . Children with non‐O blood group had almost four times higher odds of developing sTE compared to those with O blood group.…”

“…A meta‐analyses of 38 studies showed that non‐O blood group was the most common genetic prothrombotic risk factor especially in combination with FVL . Recently, one retrospective study of children with ALL and one case–control study of cancer survivors showed that blood group non‐O is a risk factor for TE . However, the impact of ABO blood group in association with other clinical risk factors and inherited or acquired thrombophilia in children with ALL has not been evaluated.…”

Central Nervous System Complications in Children Receiving Chemotherapy or Hematopoietic Stem Cell Transplantation

“…The thrombosis can occur both in central and peripheral veins, occasionally involving the arterial system. Cerebral sinus venous represents the main CNS localization (Figure 5), accounting for about 8% of all thrombotic events (114). As regard ALL, the Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase study reported a prevalence of asymptomatic thrombosis of 36.7% as opposed to only 5% of symptomatic events (115).…”

Advances in predicting venous thromboembolism risk in children

“…Recently, Spavor et al () utilised clinical variables in 218 survivors of childhood cancer from a Canadian multicentre case control study to identify children at increased DVT risk at the time of their cancer diagnosis. From these, 63 patients suffering symptomatic DVT confirmed by objective imaging tests during their cancer treatment were considered as cases and 155 cancer survivors without DVT, but with matching demographic data, were used as controls.…”

“…Given that 7-14% of paediatric oncology patients will experience a symptomatic DVT and over 40% will experience an asymptomatic DVT as a secondary adverse outcome of cancer treatment (Bajzar et al, 2006), it is of eminent importance for clinical management to determine sub-groups of children with increased risk for DVT. Recently, Spavor et al (2016) utilised clinical variables in 218 survivors of childhood cancer from a Canadian multicentre case control study to identify children at increased DVT risk at the time of their cancer diagnosis. From these, 63 patients suffering symptomatic DVT confirmed by objective imaging tests during their cancer treatment were considered as cases and 155 cancer survivors without DVT, but with matching demographic data, were used as controls.…”